Literature DB >> 3257934

Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection.

C Anastassakos1, G J Alexander, R A Wolstencroft, J A Avery, B C Portmann, G S Panayi, D C Dumonde, A L Eddleston, R Williams.   

Abstract

Abnormalities of lymphocyte proliferation in chronic hepatitis B virus infection are well documented, although the underlying mechanisms are poorly understood. To determine whether these defects may be secondary to disordered lymphokine production, we have simultaneously assayed interleukin-1 and interleukin-2 production in 31 chronic carriers of the hepatitis B virus. Supernatants from mononuclear cells cultured both in the presence and absence of lipopolysaccharide contained significantly increased quantities of interleukin-1 activity in patients compared with normal controls (p less than 0.01). Lysates of monocytes from patients also contained more interleukin-1 than those of controls (p less than 0.05) in the presence of lipopolysaccharide or silica, or both. These results indicate that interleukin-1 production is markedly elevated in patients with chronic hepatitis B virus infection, whereas in contrast, interleukin-2 production was found to be reduced in these patients (p less than 0.01). As one of the biological properties of interleukin-1 is to stimulate fibroblasts to produce collagen, the relationship between fibrosis in the liver biopsy specimen and interleukin production was examined. There was a highly significant correlation (p less than 0.001) between interleukin-1 production and the severity of fibrosis, suggesting that this lymphokine may be closely related to the development of cirrhosis in such patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257934     DOI: 10.1016/0016-5085(88)90559-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

Review 1.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 2.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.

Authors:  Francisca Monsalve-De Castillo; Tania A Romero; Jesús Estévez; Luciana L Costa; Ricardo Atencio; Leticia Porto; Diana Callejas
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

4.  Interleukin-1 alpha gene-transcription in murine keratinocytes is inhibited by HSV-1 infection.

Authors:  C Enk; E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Induction of interleukin-1 alpha and beta gene transcription in mouse peritoneal exudate cells after intraperitoneal infection with herpes simplex virus-1.

Authors:  E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 6.  Liver disease.

Authors:  S D Ryder; R Williams
Journal:  Postgrad Med J       Date:  1994-03       Impact factor: 2.401

7.  Interleukin-1 beta in chronic hepatitis C virus infection.

Authors:  E Ozyilkan; G Tatar; A Hacibektaşoglu; B Kayhan; H Telatar
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

8.  Colchicine therapy for hepatic murine schistosomal fibrosis: image analysis and serological study.

Authors:  A A Badawy; N M el-Badrawy; M M Hassan; F A Ebeid
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

9.  Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.

Authors:  Y Sawayama; J Hayashi; Y Kawakami; N Furusyo; I Ariyama; Y Kishihara; K Ueno; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

10.  Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis.

Authors:  K D Sekiyama; M Yoshiba; A W Thomson
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.